Fundamental Analysis of SALARIUS PHARMACEUTICALS INC(NASDAQ:SLRX) stock

Fundamental Rating

Overall SLRX gets a fundamental rating of 2 out of 10. We evaluated SLRX against 565 industry peers in the Biotechnology industry. The financial health of SLRX is average, but there are quite some concerns on its profitability. SLRX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SLRX has reported negative net income.

SLRX had a negative operating cash flow in the past year.

SLRX had negative earnings in each of the past 5 years.

In the past 5 years SLRX always reported negative operating cash flow.

1.2 Ratios

SLRX has a Return On Assets of -181.82%. This is amonst the worse of the industry: SLRX underperforms 89.30% of its industry peers.

Looking at the Return On Equity, with a value of -272.02%, SLRX is doing worse than 73.44% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-181.82%
ROE	-272.02%
ROIC	N/A

ROA(3y)-145.82%

ROA(5y)-103.7%

ROE(3y)-191.58%

ROE(5y)-135.06%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SLRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SLRX has less shares outstanding than it did 1 year ago.

The number of shares outstanding for SLRX has been increased compared to 5 years ago.

The debt/assets ratio for SLRX is higher compared to a year ago.

2.2 Solvency

SLRX has an Altman-Z score of -35.80. This is a bad value and indicates that SLRX is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -35.80, SLRX is doing worse than 91.44% of the companies in the same industry.

SLRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-35.8

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.98 indicates that SLRX has no problem at all paying its short term obligations.

SLRX's Current ratio of 2.98 is on the low side compared to the rest of the industry. SLRX is outperformed by 65.06% of its industry peers.

SLRX has a Quick Ratio of 2.98. This indicates that SLRX is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of SLRX (2.98) is worse than 63.10% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.98
Quick Ratio	2.98

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SLRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.35%, which is quite impressive.

EPS 1Y (TTM)37.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-65.9%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

SLRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.22% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y21.55%

EPS Next 2Y-33.44%

EPS Next 3Y5.22%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLRX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLRX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-33.44%

EPS Next 3Y5.22%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SLRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SALARIUS PHARMACEUTICALS INC

NASDAQ:SLRX (11/18/2024, 8:00:01 PM)

1.38

+0.04 (+2.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.99M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-181.82%
ROE	-272.02%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.98
Quick Ratio	2.98
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)37.35%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y21.55%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

SALARIUS PHARMACEUTICALS INC (SLRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens